Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Many compounding pharmacies, both 503A and 503B facilities believe that this does not restrict their ability to compound this drug, but rather it just limits their ability to make what the FDA refers to as an essential copy going forward to fill the gap created by the drug shortage
The retail price for either product runs around $1,000 to $1,350 per month without insurance
Pfizer (eliminated): The discontinuation of danuglipron in April 2025 eliminated the most advanced competing oral small-molecule GLP-1 program
Gorgeous data
What matters most is: The receptor pathways activated (single, dual, or triple agonism) The degree of weight loss achieved at clinical endpoints The tolerability profile at each dose escalation By these measures, Retatrutides dosing strategy has set a new benchmark for weight-loss drugs currently under development
US$ 27.32
US$ 26.98
US$ 20.10
